Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,343.72
(
-0.39%
)
US TECH 100
22,228.00
(
-1.22%
)
Dow Jones
45,216.14
(
0.11%
)
Brent Oil
106.95
(
-1.50%
)
Bitcoin
67,698.70
(
1.49%
)
News Focus
News Focus
Post# of 257314
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122824
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: tinkershaw post# 111414

Thursday, 12/23/2010 8:04:13 PM

Thursday, December 23, 2010 8:04:13 PM

Post# of 257314
Treble damages are unlikely to be awarded against a company that launches a generic after winning in the US District Court. That’s why I think NVS/MNTA may be willing to launch generic Copaxone after a win in the District Court (assuming they have FDA approval) even if the Appellate Court has not yet ruled.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today